Scarica l'app Stockscreener
749.92
0.46%
-3.49
Dopo l'orario di chiusura:
748.89
-1.03
-0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs - Benzinga
Kisunla From Eli Lilly - Pharmacy Times
Is Now a Good Time to Buy the Dip in Eli Lilly Stock? - The Motley Fool
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Eli Lilly, Verge announce milestones in ALS collaboration - Yahoo Finance
Eli Lilly Teams With Laekna For Innovative Obesity Treatment - Finimize
Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’ - Insider Monkey
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug - Reuters
Oceanside Unified takes on Eli Lilly and CVS Caremark in insulin pricing lawsuit - CBS News 8
Eli Lilly and China-based biotech Laekna team on obesity drug - TipRanks
Eli Lilly in pact with Chinese biotech for novel weight loss therapy - Seeking Alpha
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Australia
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday - Investing.com
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity - BioSpace
Lilly to develop ALS therapeutics against targets identified under Verge collaboration - BioWorld Online
Is Novo Nordisk Stock a Buy Right Now? - The Motley Fool
Is It Time to Sell Eli Lilly and Pfizer Stocks? - The Motley Fool
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley - Yahoo Finance
Eli Lilly: Procter & Gamble CEO joins board - Marketscreener.com
Eli Lilly and Company (LLY) Announces Board Changes: Jon Moeller Joins, Karen Walker Resigns - GuruFocus.com
Eli Lilly & Co Appoints Procter & Gamble CEO to Board - TipRanks
Eli Lilly appoints Jon Moeller to board of directors - TipRanks
Eli Lilly & Co. stock rises Tuesday, still underperforms market - MarketWatch
Eli Lilly & Co. (LLY) Announces Board Changes - StreetInsider.com
Lilly announces changes on board of directors - Yahoo Finance
Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley - Yahoo Finance
Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial - CNBC
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip? - Benzinga
Eli Lilly Canada ‘disappointed’ by CDA-AMC’s Final Recommendation for Ebglyss - TipRanks
Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity Fund - Yahoo Finance
Lilly’s Lp(a) targeting candidate muvalaplin meets primary endpoint in Phase 2 trial - World Pharmaceutical Frontiers
Eli Lilly announces positive Phase 2 results for Muvalaplin against heart disease - OutSourcing-Pharma.com
Lilly pill cuts genetic form of cholesterol nearly 86% in study - Reuters.com
Cramer's Lightning Round: Eli Lilly is a buy - NECN
Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels - Seeking Alpha
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Reuters
Lilly’s muvalaplin lowered lipoprotein(a) levels in adults in Phase 2 trial - TipRanks
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose - Investors | Eli Lilly and Company
Eli Lilly follows J&J in suing Biden administration over 340B rebates - Healthcare Dive
Tesla, Eli Lilly lead market cap stock movers on Monday By Investing.com - Investing.com South Africa
Revisto, Inc announced that it has received $4 million in funding from LiveOak Ventures, Eli Lilly and Company, TAU VENTURES, Arkin Digital Health - Marketscreener.com
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure - Benzinga
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints - Marketscreener.com
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF - Clinical Trials Arena
Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients (NYSE:LLY) - Seeking Alpha
Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Colorado Springs Gazette
Eli Lilly: positive results for tirzepatide - Marketscreener.com
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now - The Motley Fool
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand? - Yahoo! Voices
Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity - Investors | Eli Lilly and Company
Eli Lilly Says HHS Ignores Drug Discount Double-Dipping - Law360
Lilly Sues U.S. to Change Hospital Drug Discount Payments - The Wall Street Journal
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Lilly Sues HHS for Ending Planned 340B Drug Program Cash Rebates - Bloomberg Law
2.51%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):